MSB News: Mesoblast Resubmits Biologic License Application (BLA) to FDA for Remestemcel-L in Children With Ste - 1st Feb 2023, 10:30am

annb0t

Top 20
Mesoblast Limited

Validation of Remestemcel-L Potency Assay used in the Phase 3 Trial which Measures In-Vivo Activity based on Mechanism of Action

Assay Identifies High-Potency Product Lots Associated with Enhanced Survival

New Data Show that Remestemcel-L Improves Inflammatory Biomarkers and Survival in Children at Highest Risk of Mortality

New 4-Year Data from the Phase 3 Trial Shows Durable Long-Term Survival Outcomes

BLA Resubmission will have a Review Period up to Six-Months from Filin...

>>> Read more: Mesoblast Resubmits Biologic License Application (BLA) to FDA for Remestemcel-L in Children With Steroid-Refractory Acute Graft Versus Host Disease (Sr-aGVHD)
 
Top Bottom